Who knew? Der­mi­ra’s board kept watch as its stock price tracked Eli Lil­ly’s se­cret bid­ding on a $1.1B buy­out

Last year
Deals

#JPM20 ex­clu­sive: Olivi­er Brandi­court fol­lows the Big Phar­ma CEO path to pri­vate eq­ui­ty, join­ing Black­stone ahead of a mam­moth fund de­but

Last year
People
R&D

Watch live: End­points at #JPM20

Last year

Just how big is the bio­phar­ma deal­mak­ing world? In 2019 we saw mega­bil­lions in cash change hands, and that's just the tip of the ice­berg

Last year
Deals

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

Last year
Special
Pharma

Paul Biondi's track record at Bris­tol-My­ers cov­ered bil­lions in deals of every shape and size. Here's the com­plete break­down

Last year
R&D

The big drug hunters: No­var­tis’ $28B-plus deal spree makes Vas Narasimhan one of the top deal­mak­ers of our time

Last year

Stephen Hahn gets through Sen­ate’s soft­ball job in­ter­view — but most­ly plays dodge­ball on the is­sues fac­ing the FDA

Last year
Bioregnum
Opinion

Eliz­a­beth War­ren pro­pos­es us­ing com­pul­so­ry li­cens­ing, an­titrust ac­tions to break bio­phar­ma’s con­trol of drug pric­ing — and here are the block­busters she’s tar­get­ing first

Last year
Bioregnum
Pharma

Alzheimer's break­through? Not so fast — ex­perts poke holes in da­ta un­der­ly­ing Chi­na's sur­prise ap­proval

Last year
China
In Focus

As CRISPR hori­zons cloud, a start­up fo­cus­es on the next big thing with pow­er­house po­ten­tial — the RNA edit­ing plat­form

Last year
Startups

Worth­less? Short at­tack on Fi­bro­Gen claims their ane­mia drug roxa has a lethal Achilles’ heel — and it’s go­ing down

Last year
R&D
Pharma

Vivek Ra­maswamy trades top ex­ecs and adds stealthy vant to $3B sale, while his new part­ner toss­es My­ovant $350M

Last year
Deals

Google’s ven­ture arm re­cruits a Har­vard/Tesaro vet to help plant the seeds for a sec­ond on­col­o­gy R&D rev­o­lu­tion

Last year
People
Financing

From $0 to $12B in an in­stant. Here's why bio­phar­ma loves risky Alzheimer's stud­ies

Last year
Bioregnum
R&D

The $102B club: The top 15 R&D spenders in the glob­al bio­phar­ma busi­ness — 2019 edi­tion

3 years ago
R&D
Special

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron talks about a new era at GSK

3 years ago

Court green-lights Clo­vis case af­ter de­tail­ing ev­i­dence the board ‘ig­nored red flags’ on false safe­ty and ef­fi­ca­cy da­ta

3 years ago
R&D

‘There are mo­ments’: Sanofi’s new CEO is think­ing through the R&D strat­e­gy — and on­col­o­gy will be key

3 years ago
Bioregnum
Opinion

Biotechs are spend­ing record sums on R&D — should that wor­ry you at least a lit­tle?

3 years ago
R&D

A mi­cro­cap biotech salves old wounds with pos­i­tive PhII re­port on sta­tus epilep­ti­cus, but plen­ty of ques­tions re­main

3 years ago
R&D

Ver­tex buys the top spot on the list of the biggest pre­clin­i­cal M&A deals. Were they robbed or was it a steal?

3 years ago
Deals

Worst. biotech. deal. ever? Turns out Ab­b­Vie has plen­ty of com­pe­ti­tion for that ti­tle

3 years ago
Deals
R&D

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

3 years ago
FDA+
First page Previous page 78910111213 Next page Last page